Baili Tianheng (688506) announced on the evening of May 26 that the phase III clinical trial of the innovative biopharmaceutical BL-M07D1 (HER2-ADC) single drug independently developed by the company for locally advanced or metastatic HER2-positive breast cancer has recently completed the enrollment of the first test subjects. BL-M07D1 is an ADC drug targeting HER2. Its indications are solid tumors such as breast cancer, gastric cancer, non-small cell lung cancer, gynecological tumors, and urinary system tumors.
百利天恒：注射用BL-M07D1用于局部晚期或转移性HER2阳性乳腺癌III期临床试验完成首例受试者入组
Baili Tianheng: Injectable BL-M07D1 for locally advanced or metastatic HER2-positive breast cancer phase III clinical trial completed the first patient enrollment
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.